ASND N logo

Ascendis Pharma BMV:ASND N Stock Report

Last Price

Mex$2.61k

Market Cap

Mex$163.6b

7D

0%

1Y

23.6%

Updated

22 Dec, 2024

Data

Company Financials +

ASND N Stock Overview

A biopharmaceutical company, focuses on developing therapies for unmet medical needs. More details

ASND N fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Ascendis Pharma A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ascendis Pharma
Historical stock prices
Current Share PriceUS$2,614.00
52 Week HighUS$2,614.00
52 Week LowUS$2,090.00
Beta0.65
1 Month Change2.15%
3 Month Changen/a
1 Year Change23.59%
3 Year Change-15.82%
5 Year Changen/a
Change since IPO282.16%

Recent News & Updates

Recent updates

Shareholder Returns

ASND NMX BiotechsMX Market
7D0%0%0%
1Y23.6%0%0%

Return vs Industry: ASND N exceeded the MX Biotechs industry which returned -1.9% over the past year.

Return vs Market: ASND N exceeded the MX Market which returned -14% over the past year.

Price Volatility

Is ASND N's price volatile compared to industry and market?
ASND N volatility
ASND N Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: ASND N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine ASND N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006879Jan Mikkelsenascendispharma.com

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Ascendis Pharma A/S Fundamentals Summary

How do Ascendis Pharma's earnings and revenue compare to its market cap?
ASND N fundamental statistics
Market capMex$163.60b
Earnings (TTM)-Mex$8.93b
Revenue (TTM)Mex$6.86b

23.9x

P/S Ratio

-18.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ASND N income statement (TTM)
Revenue€327.43m
Cost of Revenue€49.69m
Gross Profit€277.74m
Other Expenses€704.23m
Earnings-€426.49m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-7.14
Gross Margin84.82%
Net Profit Margin-130.26%
Debt/Equity Ratio-718.1%

How did ASND N perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 11:29
End of Day Share Price 2024/12/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ascendis Pharma A/S is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Michelle GilsonCanaccord Genuity
Alethia YoungCantor Fitzgerald & Co.